Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Meta-analysis of IIb/IIIa Inhibition in PCI for 30- Day Mortality EPIC EPILOG RAPPORT CAPTURE Impact I Impact II Restore Epistent Espirit ISAR 2 Admiral Cadillac IIb/IIIa Inhibitor Better Placebo Better N 2099 2792 483 1265 150 4010 2141 2399 2064 401 300 2082 Ctrl 1.7 0.7 2.1 1.3 2.0 1.1 0.7 0.6 0.6 4.5 6.6 2.3 Trt 1.5 0.4 2.5 1.0 1.0 0.7 0.8 0.5 0.4 2.0 3.4 1.9 Combined 0.73 (0.55,0.96) P=.024 20186 1.3 0.9 0.1 1 10 OR Kong DF, et al. Am J Cardiol. 2003;92:651-655. (with permission)
- Page 1 and 2: P come piastrine, come prezzemolo
- Page 3 and 4: Formazione del trombo nelle ACS sen
- Page 5 and 6: GP IIb-IIIa Inhibitors costituiscon
- Page 8 and 9: Cardiologia “De Gasperis”- Nigu
- Page 10 and 11: Inibitori GPIIb/IIIa Artist’s con
- Page 12: Characteristics of GP IIb/IIIa Inhi
- Page 15 and 16: Patogenesi delle Sindromi Coronaric
- Page 17 and 18: Sindromi Coronariche Acute ST-segme
- Page 19: 8 16 Lancet 1997; 349:1429-35 35
- Page 23 and 24: Glycoprotein IIb/IIIa IIIa inhibito
- Page 25 and 26: IV GP IIb/IIIa Inhibitors in ACS: D
- Page 27 and 28: IIb/IIIa: Strategia upstream o down
- Page 29 and 30: ISAR-COOL - Trial design - High Ris
- Page 31 and 32: Messaggio Conta il rischio!
- Page 33 and 34: TIMI Risk Score For UA/NSTEMI • A
- Page 35 and 36: Gli inibitori GP IIb/IIIa IIIa ridu
- Page 37 and 38: SCA: UA/NSTEMI Le linee guida
- Page 39 and 40: ESC PCI guidelines 2004 2004 Recomm
- Page 41 and 42: Guidelines Applied in Practice (GAP
- Page 43 and 44: Possibili motivi di non adesione al
- Page 45 and 46: Sindromi Coronariche Acute ST-segme
- Page 47 and 48: Fisiologia delle sindromi coronaric
- Page 49 and 50: Abciximab During Primary Stenting G
- Page 51 and 52: A C E ONE-YEAR SURVIVAL Kaplan-Meie
- Page 53 and 54: ESC PCI guidelines 2004 2004 Recomm
- Page 55 and 56: BMS and abciximab display a synergi
- Page 57 and 58: % 50 45 40 35 30 25 20 15 10 5 P=0.
- Page 59 and 60: STEMI IIb/IIIa con trombolitico, se
- Page 61 and 62: GUSTO V AMI Primary Endpoint: 30 Da
- Page 63 and 64: Oral GPIIb/IIIa Inhibitors & Mortal
- Page 65 and 66: ISAR-REACT: 30 Day Endpoints 6 Deat
Meta-analysis of <strong>IIb</strong>/<strong>IIIa</strong> Inhib<strong>it</strong>ion in PCI for 30-<br />
Day Mortal<strong>it</strong>y<br />
EPIC<br />
EPILOG<br />
RAPPORT<br />
CAPTURE<br />
Impact I<br />
Impact II<br />
Restore<br />
Epistent<br />
Espir<strong>it</strong><br />
ISAR 2<br />
Admiral<br />
Cadillac<br />
<strong>IIb</strong>/<strong>IIIa</strong> Inhib<strong>it</strong>or Better<br />
Placebo Better<br />
N<br />
2099<br />
2792<br />
483<br />
1265<br />
150<br />
4010<br />
2141<br />
2399<br />
2064<br />
401<br />
300<br />
2082<br />
Ctrl<br />
1.7<br />
0.7<br />
2.1<br />
1.3<br />
2.0<br />
1.1<br />
0.7<br />
0.6<br />
0.6<br />
4.5<br />
6.6<br />
2.3<br />
Trt<br />
1.5<br />
0.4<br />
2.5<br />
1.0<br />
1.0<br />
0.7<br />
0.8<br />
0.5<br />
0.4<br />
2.0<br />
3.4<br />
1.9<br />
Combined<br />
0.73 (0.55,0.96)<br />
P=.024<br />
20186<br />
1.3<br />
0.9<br />
0.1 1 10<br />
OR<br />
Kong DF, et al. Am J Cardiol. 2003;92:651-655. (w<strong>it</strong>h permission)
Change language